Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Image evaluation and breast density categories as a function of mammary positioning in full-field digital mammography.

Nakano IT, Salvador GLO, Schelin HR, Denyak V, Khoury HJ, Tacara S.

Acta Radiol. 2019 Nov 7:284185119884678. doi: 10.1177/0284185119884678. [Epub ahead of print] No abstract available.

PMID:
31698930
2.

Impact of modern media on analgesic requirements during extracorporeal shockwave lithotripsy.

El-Khoury HJ, Brookes JDL, Tan B, Shahbaz S, McCahy PJ.

ANZ J Surg. 2019 Sep 30. doi: 10.1111/ans.15446. [Epub ahead of print]

PMID:
31566281
3.

REDUCTION OF STAFF RADIATION DOSE IN PROSTATIC ARTERY EMBOLISATION.

Andrade G, Garzón WJ, Khoury HJ, Savignon J, de Barros VSM, Fernandes JL, Abud DG.

Radiat Prot Dosimetry. 2019 Apr 29. pii: ncz121. doi: 10.1093/rpd/ncz121. [Epub ahead of print]

PMID:
31034554
4.

Evaluation of the MOSkin dosimeter for diagnostic X-ray CT beams.

Mendes Pereira L, Khoury HJ, Andrade MEA, Barros VSM, Cutajar D, Rosenfeld AB.

Phys Med. 2019 Apr;60:150-155. doi: 10.1016/j.ejmp.2019.03.030. Epub 2019 Apr 5.

PMID:
31000076
5.

RADIATION DOSES TO ANAESTHETISTS DURING PROSTATIC ARTERY EMBOLIZATION INTERVENTIONAL PROCEDURES.

Garzón WJ, Khoury HJ.

Radiat Prot Dosimetry. 2019 Jan 21. doi: 10.1093/rpd/ncy295. [Epub ahead of print]

PMID:
30668847
6.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27.

PMID:
30480777
7.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

8.

The performance of a multi guard ring (MGR) diode for clinical electron beams dosimetry.

Nascimento CR, Asfora VK, Gonçalves JAC, Khoury HJ, Barros VSM, Kalil LF, Bueno CC.

Appl Radiat Isot. 2018 Nov;141:112-117. doi: 10.1016/j.apradiso.2018.07.002. Epub 2018 Jul 3.

PMID:
30212784
9.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

10.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C; GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee.

Haematologica. 2018 Oct;103(10):1708-1719. doi: 10.3324/haematol.2017.182550. Epub 2018 Aug 3.

11.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249. Epub 2018 May 17.

12.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

13.

A Large Stone Within a Ureteroceles: A Diagnostic Pitfall and the Utility of Holmium Laser Deroofing as a Viable Surgical Option.

El-Khoury HJ, Aw HC, Gilbourd D, Liu MI.

J Endourol Case Rep. 2018 Feb 1;4(1):18-20. doi: 10.1089/cren.2017.0139. eCollection 2018.

14.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

15.

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH.

Ann Oncol. 2018 Mar 1;29(3):578-587. doi: 10.1093/annonc/mdy019. Review.

16.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, Bauer S, Kim AS, Roberts D, Al-Kadhimi Z, Bodo I, Winton E, Arellano M, DiPersio JF.

Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.

17.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, Andoh A, Antun AG, Barclay S, Josephson CD, Koff JL, Khoury HJ, Langston AA, Zimring JC, Roback JD, Giver CR.

Biol Blood Marrow Transplant. 2018 May;24(5):973-982. doi: 10.1016/j.bbmt.2018.01.003. Epub 2018 Jan 4.

18.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21.

19.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

20.

Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK.

Hematol Rep. 2017 Sep 26;9(3):7083. doi: 10.4081/hr.2017.7083. eCollection 2017 Sep 26. No abstract available.

21.

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.

Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e71-e73. doi: 10.1016/j.clml.2017.09.004. Epub 2017 Sep 19.

PMID:
29032022
22.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

23.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.

Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.

24.

The safety of Bosutinib for the treatment of chronic myeloid leukemia.

Kong JH, Khoury HJ, Kim AS, Hill BG, Kota V.

Expert Opin Drug Saf. 2017 Oct;16(10):1203-1209. doi: 10.1080/14740338.2017.1363176. Epub 2017 Sep 5. Review.

PMID:
28774214
25.

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.

Khoury HJ, Williams LA, Atallah E, Hehlmann R.

Am Soc Clin Oncol Educ Book. 2017;37:468-479. doi: 10.14694/EDBK_175712.

26.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.

Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar RR, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, Khoury HJ, Khuri FR, Boise LH, Lonial S, Chen F, Chen J, Lin R.

J Biol Chem. 2017 Jun 16;292(24):10142-10152. doi: 10.1074/jbc.M117.788778. Epub 2017 May 3.

27.

Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.

Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W.

Cancer. 2017 Sep 1;123(17):3346-3355. doi: 10.1002/cncr.30737. Epub 2017 Apr 27.

28.

Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.

Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS, Reddy A, Nishimoto KP, Sen D, Wirth ED 3rd, Case CC, DiPersio JF.

Cancer. 2017 Aug 15;123(16):3061-3072. doi: 10.1002/cncr.30696. Epub 2017 Apr 14.

29.

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.

Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L.

Oncogene. 2017 Jul 20;36(29):4224-4232. doi: 10.1038/onc.2017.90. Epub 2017 Apr 3.

PMID:
28368397
30.

Improved survival after acute graft-versus-host disease diagnosis in the modern era.

Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J.

Haematologica. 2017 May;102(5):958-966. doi: 10.3324/haematol.2016.156356. Epub 2017 Mar 16.

31.

Radiation Exposure of Patients and Interventional Radiologists during Prostatic Artery Embolization: A Prospective Single-Operator Study.

Andrade G, Khoury HJ, Garzón WJ, Dubourcq F, Bredow MF, Monsignore LM, Abud DG.

J Vasc Interv Radiol. 2017 Apr;28(4):517-521. doi: 10.1016/j.jvir.2017.01.005. Epub 2017 Mar 2.

PMID:
28259503
32.

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.

Cancer. 2017 Jul 1;123(13):2482-2488. doi: 10.1002/cncr.30608. Epub 2017 Feb 27.

33.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.

Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W; Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin.

Cancer. 2017 Jun 1;123(11):2035-2042. doi: 10.1002/cncr.30567. Epub 2017 Jan 24.

34.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M.

Cancer. 2017 Jun 1;123(11):2025-2034. doi: 10.1002/cncr.30536. Epub 2017 Jan 24.

35.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J.

Cell Metab. 2017 Feb 7;25(2):358-373. doi: 10.1016/j.cmet.2016.12.010. Epub 2017 Jan 12.

36.

Mathematical modelling of scanner-specific bowtie filters for Monte Carlo CT dosimetry.

Kramer R, Cassola VF, Andrade ME, de Araújo MW, Brenner DJ, Khoury HJ.

Phys Med Biol. 2017 Feb 7;62(3):781-809. doi: 10.1088/1361-6560/aa5343. Epub 2017 Jan 10.

PMID:
28072578
37.

Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.

Fan J, Lin R, Xia S, Chen D, Elf SE, Liu S, Pan Y, Xu H, Qian Z, Wang M, Shan C, Zhou L, Lei QY, Li Y, Mao H, Lee BH, Sudderth J, DeBerardinis RJ, Zhang G, Owonikoko T, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Kang S, Doetsch PW, Lonial S, Boggon TJ, Curran WJ, Chen J.

Mol Cell. 2016 Dec 1;64(5):859-874. doi: 10.1016/j.molcel.2016.10.014. Epub 2016 Nov 17.

38.

PiN photodiode performance comparison for dosimetry in radiology applications.

Oliveira CN, Khoury HJ, Santos EJ.

Phys Med. 2016 Dec;32(12):1495-1501. doi: 10.1016/j.ejmp.2016.10.018. Epub 2016 Nov 16.

PMID:
27865669
39.

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Bufarull RM, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W.

Am J Hematol. 2017 Jan;92(1):42-49. doi: 10.1002/ajh.24575. Epub 2016 Nov 12.

40.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf TH, Gambacorti-Passerini C.

Am J Hematol. 2016 Dec;91(12):1206-1214. doi: 10.1002/ajh.24536. Epub 2016 Sep 15.

41.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.

Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W.

Cancer. 2016 Oct;122(19):3005-3014. doi: 10.1002/cncr.30140. Epub 2016 Jun 17.

42.

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, Flowers CR, Kota VK, Al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.

PMID:
27297665
43.

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.

Elf S, Lin R, Xia S, Pan Y, Shan C, Wu S, Lonial S, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, Fan J, Chen J.

Oncogene. 2017 Jan 12;36(2):254-262. doi: 10.1038/onc.2016.196. Epub 2016 Jun 6.

44.

Dosimetric evaluation of X-ray examinations of paranasal sinuses in pediatric patients.

Cantalupo Bde L, Xavier AC, da Silva CM, Andrade ME, de Barros VS, Khoury HJ.

Radiol Bras. 2016 Mar-Apr;49(2):79-85. doi: 10.1590/0100-3984.2015.0081.

45.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.

PMID:
27133948
46.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28. Review.

47.

Prostatic artery embolization: radiation exposure to patients and staff.

Garzón WJ, Andrade G, Dubourcq F, Abud DG, Bredow M, Khoury HJ, Kramer R.

J Radiol Prot. 2016 Jun;36(2):246-54. doi: 10.1088/0952-4746/36/2/246. Epub 2016 Mar 30.

PMID:
27025551
48.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W; Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1024-1029. doi: 10.1016/j.bbmt.2016.02.013. Epub 2016 Feb 21.

49.

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Rosshandler Y, Shen AQ, Cortes J, Khoury HJ.

Expert Rev Hematol. 2016 May;9(5):419-24. doi: 10.1586/17474086.2016.1151351. Epub 2016 Apr 21. Review.

PMID:
26853281
50.

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.

Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J.

Blood Cancer J. 2015 Dec 11;5:e376. doi: 10.1038/bcj.2015.104. No abstract available.

Supplemental Content

Loading ...
Support Center